Literature DB >> 6398268

L-Asparaginase diabetes mellitus in rabbits: differing effects of two different schedules of L-asparaginase administration.

R L Lavine, D M DiCinto.   

Abstract

The diabetogenic effect of daily injections of 1000 i.u./kg body wt. E coli L-asparaginase was studied in male New Zealand white rabbits and compared with the diabetogenic effect of a single bolus of 10,000 I.U. E coli L-asparaginase/kg body wt. to determine whether the schedule of administration of the drug altered the diabetic syndrome produced. A daily injection of 1000 i.u. L-asparaginase/kg. body wt. was continued for 30 days. During this time glucose levels in rabbits allowed free access to food rose steadily, reaching levels of 717 +/- 63 mg/dl the day after the last injection. Levels of immunoreactive insulin fell, reaching their nadir, 53 +/- 4 pg/ml (approximately 50% of baseline) at 25 days. Glucose levels declined when therapy was discontinued, but remained significantly above control levels 46 days after insulin injections were stopped. (Glucose levels in L-asparaginase-treated groups vs. those in controls on day 46 after discontinuation: 116 +/- 3 vs. 104 +/- 1 mg/dl; P less than 0.0025.) Levels of immunoreactive insulin rose when therapy ended, reaching control levels 17 days after discontinuation. In contrast, a single bolus injection of 10,000 I.U. L-asparaginase/kg resulted in hyperglycemia with hyperinsulinemia. These data suggest that L-asparaginase can induce either a hypoinsulinemic or a hyperinsulinemic diabetic syndrome depending on the schedule of administration of the L-asparaginase and that a mild abnormality in glucose homeostasis persists after discontinuation of L-asparaginase therapy.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6398268     DOI: 10.1055/s-2007-1014907

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  4 in total

1.  Clinical consequences of hyperglycemia during remission induction therapy for pediatric acute lymphoblastic leukemia.

Authors:  J R Roberson; H L Spraker; J Shelso; Y Zhou; H Inaba; M L Metzger; J E Rubnitz; R C Ribeiro; J T Sandlund; S Jeha; C-H Pui; S C Howard
Journal:  Leukemia       Date:  2008-10-16       Impact factor: 11.528

Review 2.  Asparaginase treatment side-effects may be due to genes with homopolymeric Asn codons (Review-Hypothesis).

Authors:  Julian Banerji
Journal:  Int J Mol Med       Date:  2015-07-15       Impact factor: 4.101

3.  Diabetic ketoacidosis following PEG-asparaginase therapy

Authors:  Miriam Hinaa Ahmad; Ismat Shafiq
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2018-10-31

4.  Prevalence of transient hyperglycemia and diabetes mellitus in pediatric patients with acute leukemia.

Authors:  A Banihashem; A Ghasemi; N Ghaemi; N Moazzen; A Amirabadi
Journal:  Iran J Ped Hematol Oncol       Date:  2014-02-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.